BENITIONSClinical Trial Intelligence

Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neuromodulation in Depression

該当なし 完了 NCT05224063

対象疾患Major Depressive Disorder
該当なし
スポンサーStanford University
ステータス完了
参加者数50 名
介入(薬剤)Neuronavigated rTMS, Sham rTMS
開始日2023年1月1日
完了日2025年3月27日
結果公開日2026年7月15日

概要

Depression is a highly prevalent condition characterized by persistent low mood, energy, and activity that can affect one's thoughts, mood, behavior, and sense of well-being. Repetitive transcranial magnetic stimulation (rTMS), a non-invasive neuromodulatory technique, is an effective treatment for depression when targeting the dorsolateral prefrontal cortex (dlPFC) of the central executive network (CEN). However, remission rates are suboptimal and individual methods to target the dlPFC are lacking. In this study, we will enroll 50 patients with major depression and in a single rTMS 'dose,' prospective, randomized, double-blind, cross-over design will assess whether rTMS targeted to an individual's central executive network (CEN) assessed by single pulse TMS can enhance network modulation. If successful, this work will lead to a clinical rTMS trial comparing this personalized targeting approach against standard rTMS.

Change in TMS-evoked EEG Responses Following Intermittent Theta Burst Stimulation (iTBS)

Pre-intervention and up to 20 minutes post-intervention · dBμV

Neuronavigated rTMS4.28 ± 0.58 dBμV
Sham rTMS3.95 ± 0.48 dBμV
Neuronavigated rTMS3.92 ± 0.53 dBμV
Sham rTMS4.28 ± 0.64 dBμV

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

すべての治験

このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。